Previous 10 | Next 10 |
Sumitomo Dainippon Pharma to provide Myovant Sciences with a $350 million, low-interest, five-year term loan facility, with no repayments due until the end of the term Opportunity to access Sumitomo Dainippon Pharma’s commercial infrastructure and operational support for planned re...
Top-line results for SPIRIT 2 and SPIRIT 1 expected in the first and second quarters of 2020, respectively Studies support potential regulatory submission for a single tablet, once-daily treatment of moderate-to-severe endometriosis-associated pain BRISBANE, Calif. and BASEL, Switzerla...
BASEL, Switzerland and SAN MATEO, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Pervasive stigma and prevalent symptoms related to menstruation are among the key takeaways from a new survey conducted by Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative tr...
BRISBANE, Calif., and BASEL, Switzerland, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, announced today the formation of Female Forward Together, a cross-sector...
Biotech is in the doldrums. The SPDR S&P Biotech ETF declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...
BRISBANE, Calif., and BASEL, Switzerland, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV ), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that results from its Phase 3 LIBERTY 1 & 2 s...
Myovant Sciences' (NYSE: MYOV ) founding shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma ( OTC:SMDPY ) have announced their entry into a non-binding memorandum of understanding (MOU) for the creation of a broad strategic alliance. More news on: Myovant Sc...
Roivant’s ownership interest in Myovant Sciences (approximately 46% of shares issued and outstanding) to be fully assumed by a new entity, Sumitomo Dainippon-Roivant Alliance, which will be wholly owned by Sumitomo Dainippon Pharma Sumitomo Dainippon-Roivant Alliance to prov...
Thinly traded Myovant Sciences ( MYOV +0.1% ) has rallied ~25% since August 6 when in reported fiscal Q1 results (calendar Q2) that included a pipeline update. More news on: Myovant Sciences Ltd., AbbVie Inc., Healthcare stocks news, Read more ...
BRISBANE, Calif. and BASEL, Switzerland, Aug. 27, 2019 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated today at 8:30 AM ET. The date for Lynn Seely's presentation was incorrectly listed. The complete and corrected release follows: Myovant Sciences (NYSE: ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myovant Sciences, Ltd. ("Myovant" or "the Company") (NYSE:MYOV). Investors who purchased Myovant securities are encouraged to obtain additional infor...
Third fiscal quarter 2022 total revenue of $100.2 million ; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX ® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume ...
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire ...